Search Results - cancer%2foncology

101 Results

Sort By:

Protein Degraders of NSD2 for Targeted Treatment of Head and Neck Cancers

SHORT DESCRIPTION Targeted protein degraders that selectively eliminate NSD2 for improved treatment of head and neck cancers. INVENTORS Gary Schiltz* Weinberg College of Arts and Sciences, Department of Chemistry Yanis Boumber * Principal Investigator NU Tech ID: NU 2023-140 IP STATUS U.S....

Published: 6/16/2026 | Updated: 6/16/2026 | Inventor(s):

Keywords(s): BIO2026, Cancer/Oncology, Head and neck cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics

Category(s): Life Sciences > Therapeutics

Neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and neurodegenerative disorders

NU 2016-137B INVENTORS Richard Silverman Weinberg College of Arts and Sciences, Department of Chemistry SHORT DESCRIPTION Novel highly selective neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and other cancers with high expression of nNOS (e.g., gliomas, ovarian cancer) as well as neurodegenerative...

Published: 6/17/2026 | Updated: 6/16/2026 | Inventor(s):

Keywords(s): AD - Alzheimer’s Disease, ALS - Amyotrophic Lateral Sclerosis, AUTM26C1, BIAUTM1, BIO2026, Cancer/Oncology, HD - Huntington's Disease, Melanoma, Neurodegenerative disease, Neuroinflammation, Neurologic disease, nNOS, PD - Parkinson's Disease, Small molecule, Targeted therapy, Therapeutics

Category(s): Life Sciences > Therapeutics

Peptide Linkers for Modulating Antigen Immune Response in Cancer Vaccines

SHORT DESCRIPTION A novel non-biologically derived peptide linker technology enabling precise intracellular release of vaccine antigens to enhance immune activation. NU TECH ID NU 2024-124 INVENTORS Chad Mirkin* Weinberg College of Arts and Sciences, Department of Chemistry Tanner Fink *...

Published: 6/16/2026 | Updated: 6/16/2026 | Inventor(s):

Keywords(s): BIO2026, Cancer/Oncology, Immunology, Immunotherapy, Infectious disease, Therapeutics, Vaccine

Category(s): Life Sciences > Therapeutics

Biomimetic HDL Nanoparticles for Treatment of Cancer, Immune and Inflammatory Disorders, and Cardiovascular Disease

SHORT DESCRIPTION Self-assembling biomimetic high-density lipoprotein nanoparticle (HDL NP) platform technology with a soft organic core, designed to more closely replicate key functional properties of mature human HDL for therapeutic use in cardiovascular disease, cancer, and inflammatory/immune disorders. INVENTORS Colby Thaxton* Northwestern...

Published: 6/16/2026 | Updated: 6/16/2026 | Inventor(s):

Keywords(s): Atherosclerosis, Autoimmune disease, BIO2026, Breast cancer, Cancer/Oncology, Cardiology and Cardiovascular disease, Gene therapy, Immunology, Immunotherapy, Inflammation, Nanomaterials, Nanoparticle, Nanotechnology, Nucleic Acids, Platform technology, Prostate cancer, Research tool, Small molecule, Targeted therapy, Therapeutics

Category(s): Life Sciences > Biomarkers & Biomedical Research Tools, Life Sciences > Healthcare Devices, Tools & IT, Life Sciences > Therapeutics

Retargetable and Metabolically Tunable CAR Cell Platforms for Durable, Antigen‑Specific Cancer Therapy

SHORT DESCRIPTION A modular immunotherapy platform that combines hapten‑redirectable chimeric antigen receptor (CAR) constructs with itaconate‑programmed, memory‑like immune cells to deliver safer, more durable, and tunable antigen‑specific responses across hematologic and solid tumors. NU TECH ID NU 2023-021, NU 2024-077 INVENTORS Ashima...

Published: 6/10/2026 | Updated: 6/10/2026 | Inventor(s):

Keywords(s): Autoimmune disease, Cancer Treatment, Cancer/Oncology, Cell therapy, Immunology, Immunotherapy, Inflammation, Leukemia, Lymphoma, Targeted therapy, Therapeutics

Category(s): Life Sciences > Therapeutics

Novel Aminotransferase Inhibitor Platform for the Treatment of Cancer and Neurological Disorders

SHORT DESCRIPTION Novel Aminotransferase Mechanism-Based Inhibitor (MBI) Platform Targeting OAT and GABA-AT as Novel Treatments for Cancer and Neurological Disorders. INVENTORS Richard Silverman* Weinberg College of Arts and Sciences, Department of Chemistry * Principal Investigator DEVELOPMENT...

Published: 6/17/2026 | Updated: 6/1/2026 | Inventor(s):

Keywords(s): AD - Alzheimer’s Disease, BIO2026, Cancer/Oncology, CNS - Central Nervous System, Colon cancer, Epilepsy, Gastric cancer, Liver cancer, Lung cancer, Neurodegenerative disease, Neurologic disease, Neurology, Pancreatic cancer, PD - Parkinson's Disease, Psychiatric disorder, Small molecule, Targeted therapy, Therapeutics

Category(s): Life Sciences > Therapeutics

Fatty-Acid Modified Cytotoxins and Peptides for Improved Efficacy, Safety, and Dosing Flexibility

SHORT DESCRIPTION A suite of four complementary technologies for a long-chain fatty‑acid–guided drug delivery platform to achieve superior therapeutic outcomes with reduced toxicity across both oncology and critical care applications. INVENTORS Nathan Gianneschi*, and others Weinberg College of Arts and Sciences,...

Published: 6/2/2026 | Updated: 6/1/2026 | Inventor(s):

Keywords(s): Adjunct therapy, BIO2026, Biologic, Breast cancer, Cancer/Oncology, Chemotherapy, Colon cancer, Lung cancer, Ovarian cancer, Pancreatic cancer, Small molecule, Targeted therapy, Therapeutics

Category(s): Life Sciences > Therapeutics

Small Molecule Inhibitors of Pleckstrin-2 for Treating Myeloproliferative Neoplasms

SHORT DESCRIPTION Small molecule inhibitors of Pleckstrin-2 (Plek2) for treating cell proliferative diseases and disorders, particularly myeloproliferative neoplasms (MPNs). NU Tech IDs: NU 2018-169, NU 2021-005 PRINCIPAL INVESTIGATOR Peng Ji Northwestern University Feinberg School of Medicine, Department of Pathology IP...

Published: 5/27/2026 | Updated: 5/27/2026 | Inventor(s):

Keywords(s): Breast cancer, Cancer/Oncology, Colon cancer, Leukemia, Lung cancer, Pancreatic cancer, Small molecule, Therapeutics

Category(s): Life Sciences > Therapeutics

Incomplete Autophagy Induction for the Treatment of Cancer

SHORT DESCRIPTION This incomplete autophagy inducer triggers caspase-mediated apoptosis in cancer cells by inducing incomplete autophagy, leading to tumor reduction and improved survival. INVENTORS INVENTORS Maciej Lesniak* Northwestern University Feinberg School of Medicine, Department of Neurological Surgery Jawad...

Published: 6/16/2026 | Updated: 5/7/2026 | Inventor(s):

Keywords(s): Autophagy, BIO2026, Brain cancer, Breast cancer, Cancer/Oncology, Lung cancer, Melanoma, Repurposed Drugs, Small molecule, Therapeutics

Category(s): Life Sciences > Therapeutics

Dual-Action Inhibition Strategy for KRAS and LKB1 Mutant NSCLC

NU 2023-113 INVENTORS Lillian Eichner (Feinberg School of Medicine, Department of Biochemistry and Molecular Genetics)* Reuben Shaw (Salk Institute) SHORT DESCRIPTION A dual drug combination to target KRAS and LKB1 mutant non–small cell lung cancer that results in superior efficacy by enhancing T cell recruitment and reducing tumor burden. BACKGROUND Lung...

Published: 6/16/2026 | Updated: 4/29/2026 | Inventor(s): Reuben Shaw

Keywords(s): BIO2026, Cancer/Oncology, Lung cancer, Repurposed Drugs, Small molecule, Therapeutics

Category(s): Life Sciences > Therapeutics

1 2 3 4 5 6 7 8 9 10 ...